Stocktoria
Rallybio Corp RLYB
Rallybio Corp (RLYB) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $858,000 at a -1046.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.916 |
| Retained earnings / assets | -4.851 |
| EBIT / assets | -0.531 |
| Equity / liabilities | 13.462 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RLYB | Rallybio Corp | 3/9 | 0.76 | — | — |
| ONCO | Onconetix, Inc. | 4/9 | — | — | — |
| HYPD | HYPERION DEFI, INC. | 5/9 | -16.62 | — | — |
| RFL | Rafael Holdings, Inc. | 3/9 | 0.8 | — | — |
| MCRB | Seres Therapeutics, Inc. | 5/9 | — | 12 | — |
| BGMS | Bio Green Med Solution, Inc. | 3/9 | — | — | — |
| STTK | Shattuck Labs, Inc. | 3/9 | -3.77 | — | — |
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
FAQ
Is RLYB financially healthy?
Rallybio Corp's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does RLYB pay a dividend?
No, Rallybio Corp does not currently pay a dividend.
How profitable is RLYB?
In FY2025, Rallybio Corp had a net margin of -1046.4% and a return on equity of -15.5%.
Is RLYB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Rallybio Corp: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.